Optimizing Treatment Approaches for Newly Diagnosed Prostate Cancer: Insights from APCCC and ESMO

Optimizing Treatment Approaches for Newly Diagnosed Prostate Cancer: Insights from APCCC and ESMO

Introduction:
Prostate cancer is a common malignancy that affects millions of men worldwide. Over the years, advancements in research and technology have led to the development of various treatment options. In this article, we will explore the key takeaways from two significant conferences, APCCC 2019 and ESMO 2019, focusing on the treatment of newly diagnosed prostate cancer.

APCCC 2019: How to Treat Men with Newly Diagnosed cN1 cM0 Prostate Cancer - Surgery Options:
The APCCC 2019 conference shed light on the importance of novel imaging techniques in detecting metastases in patients with newly diagnosed prostate cancer. While these imaging methods are more sensitive than traditional modalities, the benefits of detecting metastases earlier are still unclear. It remains a question whether PET-only diagnosed metastases should be treated systematically or with aggressive local and metastases-directed therapy. However, the conference emphasized the necessity of performing an extended pelvic lymph node dissection (ePLND) in these patients, as recommended by the EAU guidelines.

ESMO 2019: Homogenizing Genomic Reports: What Clinicians Need to Know:
At ESMO 2019, the focus was on genomic reports and their implications for treatment decisions in prostate cancer. Several key genomic markers were highlighted, indicating their potential for personalizing therapy. These markers include microsatellite instability testing for immunotherapy response, DNA damage repair status for platinum therapy or PARP inhibitor selection, and AR alterations such as AR-V7 for response to anti-androgens. Additionally, the conference emphasized the importance of circulating free DNA for prognosis, PTEN loss as a possible biomarker for predicting response to AKT inhibitors, and CDK12 loss for immunotherapy response. Other markers discussed were TP53/RB1 loss, which may predict platinum sensitivity and shorter response to anti-androgen therapy, and double negative (AR negative, non-neuroendocrine cells) for response to FGFR inhibitors. PSMA expression was also identified as a potential marker for response to PSMA conjugated radionuclide therapies.

Connecting the Common Points:
While the APCCC and ESMO conferences may have focused on different aspects of newly diagnosed prostate cancer, there are common points that emerge from both. Both conferences highlighted the significance of personalized medicine and the use of genomic markers in guiding treatment decisions. The importance of advanced imaging techniques in detecting metastases and the necessity of performing an extended pelvic lymph node dissection were also emphasized. By connecting these common points, we gain a more comprehensive understanding of the optimal treatment approaches for men with newly diagnosed prostate cancer.

Actionable Advice:

1. Embrace Personalized Medicine: The integration of genomic markers into treatment decision-making is crucial. Clinicians should stay updated with the latest research and guidelines to identify patients who may benefit from targeted therapies based on their genetic profile.

2. Consider Advanced Imaging Techniques: While the benefits of detecting metastases earlier are still unclear, utilizing novel imaging methods may provide valuable insights for treatment planning. Clinicians should explore the use of PET imaging and other advanced modalities to enhance the accuracy of diagnosis and staging.

3. Collaborative Approach: It is essential for clinicians to work together with multidisciplinary teams to ensure optimal treatment outcomes for patients with newly diagnosed prostate cancer. By involving urologists, medical oncologists, radiation oncologists, and genetic counselors, individualized treatment plans can be developed to address the unique needs of each patient.

Conclusion:
The APCCC 2019 and ESMO 2019 conferences have highlighted significant advancements in the management of newly diagnosed prostate cancer. By combining the insights from these conferences, we can optimize treatment approaches by embracing personalized medicine, utilizing advanced imaging techniques, and adopting a collaborative approach. With ongoing research and advancements, the future of prostate cancer treatment holds great promise for improving patient outcomes and quality of life.